Dose Response Effects of Pecan Consumption

Phase

N/A

Condition

Obesity

Hypertriglyceridemia

Treatment

Pecan MID

CONTROL

Pecan LOW

Clinical Study ID

NCT05949879

PROJECT00007288

Ages 30-75
All Genders
Accepts Healthy Volunteers

Study Summary

The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health.

The specific aims of this study are to:

Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on fasting and postprandial blood lipids.
Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on plasma markers associated with overall health.
Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on subjective and physiologic postprandial measures of hunger and satiety.

Participants will be asked to:

Consume pecans daily for 28 days or maintain their current habitual diet.
Attend three short weekly visits for fasting blood craws, body measurements, and collect their next week's supply of study materials.
Attend two longer (5 h) testing visits which include consuming a standard breakfast meal and having their blood drawn periodically before and after breakfast.

Researchers will compare pecan LOW, pecan MID, pecan HIGH, and the Control group to examine the physiologic effects of incorporating various dosages of pecans into one's diet.

Eligibility Criteria

Inclusion

Inclusion Criteria:

30 to 75-year-old men and women at increased risk of cardiovascular disease.Increased risk of cardiovascular disease will be defined by either elevatedcholesterol profiles or overweight/obesity.
Elevated cholesterol profiles will be defined as: "Borderline High" and/or "at risk"in two or more of the following variables (total cholesterol: 180-239 mg/dL, LDLcholesterol 110- 159 mg/dL, triglycerides 130-199 mg/dL) --or---"High" in totalcholesterol (240 mg/dL and higher), LDL (160 mg/dL or higher), or triglycerides (between 200-350 mg/dl).
Overweight/obesity will be defined by body mass index (overweight > 28 kg/m2 orobesity 30 kg/m2 or greater).

Exclusion

Exclusion Criteria:

Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg/dL or LDL levels greater than 190 mg/dL plus a family history of myocardialinfarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative
Alcohol intake >3 drinks/d for males or >2 drinks/d for females
Individuals with food allergies/sensitivities to foods provided in the study,including tree nuts, gluten, and or lactose/dairy
Individuals who regularly consume nuts and/or nut butter (defined as consumption of >2 servings (~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almondbutter) per week
Individuals adhering to special diets, including, but not limited to, the ketogenicdiet, intermittent fasting, vegetarian diet, or carbohydrate-restricted diets
Plans to begin a weight loss/exercise regime during the trial
Weight gain or loss of more than 5% of their body weight in the past 3 months
History of previous or current renal or bowel disease
Females who are currently pregnant or lactating
Individuals participating in >3 hours/week of exercise
Women on hormone replacement therapy for <2 years
Fasting glucose >126 mg/dL
Blood pressure >180/120 mmHg
History of medical or surgical events that could affect digestion or swallowing
Gastrointestinal surgery, atherosclerosis, or bleeding disorders
Tobacco or nicotine use
Previous heart attack (MI) or stroke, previous or current diagnosis of cancer
Chronic or metabolic diseases
Medication use affecting digestion and absorption, medications affecting metabolism (e.g., thyroid meds), lipid-lowering medications, medications for diabetes, bloodthinning medications
Steroid/hormone therapies or current antibiotic cycles

Study Design

Pecan MID

August 01, 2023

August 01, 2026

Study Description

Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. Research investigating the relationship between pecan nut consumption and cardiometabolic outcomes has shown that pecan nut consumption can significantly benefit fasting and postprandial blood lipids, reduce CVD risk factors, promote weight maintenance, improve subjective and psychological markers of physiological appetite, increase total antioxidant capacity, and increase energy expenditure and fat oxidation. However, the current literature on pecan consumption and health outcomes only encompasses physiological benefits coming from a dosage of ~45g/day and above, which is above the current dietary guidelines. This study will be the first dose-response study examining the minimalist effective dose and determining the most effective dosage of pecan consumption on metabolic and cardiovascular outcomes. If lower doses of pecans in the diet are found to improve fasting and postprandial lipid metabolism and markers of chronic disease risk, these study findings could lead to improvements in health.

This prospective clinical study is a single-blinded, randomized control trial in adults at increased risk for cardiovascular disease (poor cholesterol profiles or overweight/obesity). There are four diet interventions: pecan LOW (6% energy from pecans), pecan MID (13% energy from pecans), pecan HIGH (20% energy from pecans), and CON (instructed to maintain their current habitual diet and abstain from any tree nut/peanut consumption for the duration of the intervention). This study protocol consists of a 28-day diet intervention that will involve substituting pecans for commonly consumed snack or meal items every day for the entire 28-day intervention or maintaining a current/usual diet.

There are a total of six testing visits: a screening visit (V0), a pre-intervention visit (V1), short weekly visits (end of weeks 1, 2, and 3; V2-V4), and a post-intervention visit (V5).

At screening (V0), qualification is confirmed based on anthropometrics and fasting blood draw, which is analyzed for a cholesterol panel and blood glucose. Additionally, energy requirements are estimated at this visit for use in the diet intervention.

At V1, participants will have anthropometrics measured, including body composition, by DEXA. Next, a certified phlebotomist places an IV catheter and takes the fasting blood sample. Then the participant consumes a high-saturated-fat meal challenge, delivering 17% of their estimated energy needs (from V0). Then the participant has blood drawn 7 times using the IV catheter over the next 4 hours.

The 28-day diet intervention will consist of research personnel providing pecans that deliver 6%, 13%, or 20% of the participant's daily energy needs (determined at V0). Participants placed in one of the three pecan diets will receive counseling at the baseline (V1) and weekly intervention visits (V2-V4) on substituting pecans for isocaloric foods from their habitual diet. Individuals randomized in the control group will be instructed to follow their habitual diet and will not be provided with any food items.

Participants return weekly (V2, V3, V4) to return study materials and collect food for the next week (if applicable). At these weekly visits, participants also have a fasting blood draw, and researchers will collect the participant's body measurements.

At the end of the 28-day dietary intervention, participants return for V5, where all procedures from V1 are repeated.

The investigators hypothesize that diets including the daily consumption of pecans will benefit health outcomes and lower cardiometabolic risk factors.

Connect with a study center

University of Georgia
Athens, Georgia 30602
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.